ATE204329T1 - Retrovirale vektoren aus gefluegel-sarcom- leukoseviren ermoeglichen den transfer von genen in saeugetierzellen und ihre therapeutischen anwendungen - Google Patents

Retrovirale vektoren aus gefluegel-sarcom- leukoseviren ermoeglichen den transfer von genen in saeugetierzellen und ihre therapeutischen anwendungen

Info

Publication number
ATE204329T1
ATE204329T1 AT96916528T AT96916528T ATE204329T1 AT E204329 T1 ATE204329 T1 AT E204329T1 AT 96916528 T AT96916528 T AT 96916528T AT 96916528 T AT96916528 T AT 96916528T AT E204329 T1 ATE204329 T1 AT E204329T1
Authority
AT
Austria
Prior art keywords
retroviral vectors
sarcoma
leukose
poultry
viruses
Prior art date
Application number
AT96916528T
Other languages
English (en)
Inventor
Eugene Barsov
Stephen H Hughes
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE204329T1 publication Critical patent/ATE204329T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96916528T 1995-05-22 1996-05-22 Retrovirale vektoren aus gefluegel-sarcom- leukoseviren ermoeglichen den transfer von genen in saeugetierzellen und ihre therapeutischen anwendungen ATE204329T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44546295A 1995-05-22 1995-05-22
PCT/US1996/007370 WO1996037625A1 (en) 1995-05-22 1996-05-22 Retrovirus vectors derived from avian sarcoma leukosis viruses permitting transfer of genes into mammalian cells and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
ATE204329T1 true ATE204329T1 (de) 2001-09-15

Family

ID=23769003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96916528T ATE204329T1 (de) 1995-05-22 1996-05-22 Retrovirale vektoren aus gefluegel-sarcom- leukoseviren ermoeglichen den transfer von genen in saeugetierzellen und ihre therapeutischen anwendungen

Country Status (8)

Country Link
US (2) US6096534A (de)
EP (1) EP0827547B1 (de)
AT (1) ATE204329T1 (de)
AU (1) AU695762B2 (de)
CA (1) CA2221708A1 (de)
DE (1) DE69614527T2 (de)
ES (1) ES2161362T3 (de)
WO (1) WO1996037625A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006760A1 (en) * 1998-07-29 2000-02-10 The Government Of The United States Of America, R Epresented By The Secretary, Department Of Health And Human Services Use of constitutive transport elements for host range control
AU2002246829A1 (en) * 2000-12-22 2002-07-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Methods to control the host range of retroviral vectors
DE60232785D1 (de) 2001-03-14 2009-08-13 Myriad Genetics Inc Tsg101-gag-wechselwirkung und ihre verwendung
US7309783B2 (en) * 2001-05-09 2007-12-18 The University Of Connecticut Mammalian early developmental regulator gene
US7132237B2 (en) * 2002-03-13 2006-11-07 Mayo Foundation For Medical Education And Research Avian leukosis viruses and polypeptide display
EP1361277A1 (de) * 2002-04-30 2003-11-12 Centre National De La Recherche Scientifique (Cnrs) Optimierung von Transgenexpression in Säugetierzellen
US7135324B2 (en) * 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
CN1756845A (zh) 2002-11-12 2006-04-05 A·B·德塞罗斯 腺病毒载体疫苗
WO2005051991A2 (en) 2003-11-24 2005-06-09 Sidney Kimmel Cancer Center Mucin antigen vaccine
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
US20060286074A1 (en) * 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
US20090180989A1 (en) * 2005-10-05 2009-07-16 Synageva Biopharma Corp. Compositions and methods for delivering nucleotide sequences to vertebrates
ES2744125T3 (es) 2005-10-05 2020-02-21 Alexion Pharma Inc Producción rápida de virus de título elevado
CA2628837C (en) * 2005-11-07 2018-11-27 Sidney Kimmel Cancer Center Cd40 ligand fusion protein vaccine
AU2007260817A1 (en) 2006-06-23 2007-12-27 Myriad Genetics, Inc. DPYD gene variants and use thereof
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US11839655B2 (en) 2017-09-01 2023-12-12 Microvax, Llc Combination cancer therapy
EP4221738A1 (de) 2020-09-30 2023-08-09 Alma Bio Therapeutics Nukleinsäuretherapie zur differentiellen modulation der wirtsmikroflora
US20240269265A1 (en) * 2021-06-09 2024-08-15 Chimeron Bio Corporation Peptide VLP-Based Vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4997763A (en) * 1987-07-31 1991-03-05 The United States Of America As Represented By The Secretary Of Agriculture Vectors for gene insertion into avian germ line
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby

Also Published As

Publication number Publication date
US6096534A (en) 2000-08-01
US6794188B2 (en) 2004-09-21
WO1996037625A1 (en) 1996-11-28
EP0827547B1 (de) 2001-08-16
DE69614527D1 (de) 2001-09-20
DE69614527T2 (de) 2002-05-16
ES2161362T3 (es) 2001-12-01
CA2221708A1 (en) 1996-11-28
EP0827547A1 (de) 1998-03-11
AU5924296A (en) 1996-12-11
AU695762B2 (en) 1998-08-20
US20020110896A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
ATE204329T1 (de) Retrovirale vektoren aus gefluegel-sarcom- leukoseviren ermoeglichen den transfer von genen in saeugetierzellen und ihre therapeutischen anwendungen
EE9700344A (et) Rekombinantne MVA viirus, eukarüootne rakk ja vaktsiin ning nende kasutamine
EA199800638A1 (ru) Смесь рекомбинантных векторов вируса коровьей оспы в качестве полиоболоченных вирусных вакцин против вируса иммунного дефицита человека
DE69125925D1 (de) Rekombinante herpes simplex virus impfstoffe und methoden
ATE211766T1 (de) Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheiten
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
DE69841982D1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
FI963717A7 (fi) Uusia mutatoituja viruksia, viruksenvastaisia yhdisteitä ja uusia menetelmiä rokotteiden valmistamiseksi
BR9202024A (pt) Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo
DE69706593D1 (de) Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier
DK0652957T3 (da) Samlede viruspartikler og deres anvendelse i en vaccine imod rotaviral sygdom
EP0261940A3 (de) Pseudorabies-Impfstoffe und DNS-Vektoren zur Rekombination mit Poxviren
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
LU91303I2 (fr) Gallivac HVT IBD- virus vivant recombinant vHVT013-69,au minimum 3,0 log 10 UFP
DK0838222T3 (da) Vaccinesammensætninger, der omfatter inaktiverede immunogener og levende kyllingeanæmi-virus (CAV)
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
DK0831899T3 (da) Rekombinant koppevirus-calicivirus-præparater og anvendelser
FI971275A7 (fi) Inaktivoidun IVa2-geenin käsittävät epätäydelliset yhdistelmä-DNA-tekn iset adenovirukset
DK498387A (da) Virus-dna-sekvens
ATE453708T1 (de) Impfstoff gegen west nile virus
MX9102757A (es) Vacuna de virus de enfermedad de marek sin celulas.
Ryndich et al. The family of env genes of avian retroviruses: molecular analysis of Rous sarcoma virus adapted to duck cells
TH55468A (th) รีคอมบิแนนท์ mva ไวรัสที่แสดงลักษณะแอนติเจนของไวรัสไข้เลือดออกและการใช้งานมันในวัคซีน

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties